NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Thursday that its first quarter revenues rose 226 percent year over year, driven by a 150 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended March 31, the diagnostics company reported revenues of $48.4 million, up from $14.8 million a year earlier, and blowing away the analyst estimate of $37.3 million.

Exact completed 100,000 Cologuard tests during the quarter, with an average recognized revenue per test of $485.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.